BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9731468)

  • 21. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
    Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
    Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein.
    Vogt M; Butz K; Dymalla S; Semzow J; Hoppe-Seyler F
    Oncogene; 2006 Jul; 25(29):4009-15. PubMed ID: 16462759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6.
    Gu Z; Pim D; Labrecque S; Banks L; Matlashewski G
    Oncogene; 1994 Feb; 9(2):629-33. PubMed ID: 8290274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes.
    Alfandari J; Shnitman Magal S; Jackman A; Schlegel R; Gonen P; Sherman L
    Virology; 1999 May; 257(2):383-96. PubMed ID: 10329549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
    García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
    Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
    Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6.
    Inoue T; Oka K; Yong-Il H; Vousden KH; Kyo S; Jing P; Hakura A; Yutsudo M
    Mol Carcinog; 1998 Mar; 21(3):215-22. PubMed ID: 9537653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
    Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
    J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
    Moon MS; Lee CJ; Um SJ; Park JS; Yang JM; Hwang ES
    Gynecol Oncol; 2001 Feb; 80(2):168-75. PubMed ID: 11161855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
    Thomas M; Pim D; Banks L
    Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions.
    Ristriani T; Masson M; Nominé Y; Laurent C; Lefevre JF; Weiss E; Travé G
    J Mol Biol; 2000 Mar; 296(5):1189-203. PubMed ID: 10698626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer.
    Hsu NY; Cheng YW; Chan IP; Ho HC; Chen CY; Hsu CP; Lin MH; Chou MC
    Oncol Rep; 2009 Jan; 21(1):81-7. PubMed ID: 19082446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.
    Thomas M; Massimi P; Jenkins J; Banks L
    Oncogene; 1995 Jan; 10(2):261-8. PubMed ID: 7838526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.
    Jiang M; Milner J
    Oncogene; 2002 Sep; 21(39):6041-8. PubMed ID: 12203116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
    Sharma BK; Ray A; Kaur S; Gupta S
    Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation.
    Liu Y; McKalip A; Herman B
    J Cell Biochem; 2000 May; 78(2):334-49. PubMed ID: 10842327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein.
    Kukimoto I; Aihara S; Yoshiike K; Kanda T
    Biochem Biophys Res Commun; 1998 Aug; 249(1):258-62. PubMed ID: 9705868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6.
    Molinari M; Milner J
    Oncogene; 1995 May; 10(9):1849-54. PubMed ID: 7753560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
    Lu DW; El-Mofty SK; Wang HL
    Mod Pathol; 2003 Jul; 16(7):692-9. PubMed ID: 12861066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
    Rampias T; Sasaki C; Weinberger P; Psyrri A
    J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.